A good example of this is the recently announced collaboration between the Mayo Clinic and Silicon Valley Biosystems (SV Bio). Genetic data is too vast and complex for any one physician, and requires computer-assisted analysis to provide relevant results. This makes third party data interpretation crucial for doctors to use the genome-based testing tool to better understand a patient's disease(s) and ultimately lead to more efficient treatment(s) with increased efficacy and decreased cost. This brings up a whole other slew of issues such as patient-privacy, which is where oversight and policy come in. Hopefully politics can avert common partisanship and instead promote the development of this society-benefiting technology.
Genome-based testing is just one example of the innovations ushering in the era of individualized medicine, an era with the potential to prevent diseases before they occur and to tailor therapies optimized for each patient's unique circumstance. Stay tuned for more exciting developments.
No comments:
Post a Comment